Familial pancreatic cancer accounts for 10% of all patients with pancreatic cancer. Because the 5-year survival rate of pancreatic cancer is only 7%, screening programs for high-risk individuals are essential and might be advantageous. Pancreatic ductal adenocarcinoma mostly shows symptoms at an advanced state and treatment is not efficient enough to cure most patients. People with hereditary tumor syndromes or their affected relatives can also be included in such screening programs. Besides the collection of data to investigate the background of the disease, these screening programs aim to diagnose and treat precursor lesions so that more dangerous, invasive lesions are prevented. These precursor lesions can be pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. This review summarizes the latest knowledge of pancreatic screening programs, shows the procedure of pancreatic cancer screening, and gives an overview of current guidelines.

1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
[PubMed]
2.
Ansari D, Tingstedt B, Andersson B, et al.: Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol 2016;12:1929-1946.
[PubMed]
3.
Kamisawa T, Wood LD, Itoi T, Takaori K: Pancreatic cancer. Lancet 2016;388:73-85.
[PubMed]
4.
Gerdes B, Kress R, Rieder H, et al.: [Familial pancreatic cancer-concept for study of the National Case Collection and early diagnosis program for high risk people]. Z Arztl Fortbild Qualitatssich 2002;96:251-255.
[PubMed]
5.
Chang JC, Kundranda M: Novel diagnostic and predictive biomarkers in pancreatic adenocarcinoma. Int J Mol Sci 2017;18:pii:E667.
[PubMed]
6.
Gungor C, Hofmann BT, Wolters-Eisfeld G, Bockhorn M: Pancreatic cancer. Br J Pharmacol 2014;171:849-858.
[PubMed]
7.
Mohammed S, Van Buren G 2nd, Fisher WE: Pancreatic cancer: Advances in treatment. World J Gastroenterol 2014;20:9354-9360.
[PubMed]
8.
De La Cruz MS, Young AP, Ruffin MT: Diagnosis and management of pancreatic cancer. Am Fam Physician 2014;89:626-632.
[PubMed]
9.
Oberstein PE, Olive KP: Pancreatic cancer: Why is it so hard to treat? Therap Adv Gastroenterol 2013;6:321-337.
[PubMed]
10.
Sellam F, Harir N, Khaled MB, et al.: Delayed diagnosis of pancreatic cancer reported as more common in a population of North African young adults. J Gastrointest Oncol 2015;6:505-510.
[PubMed]
11.
Fendrich V, Langer P, Bartsch DK: Familial pancreatic cancer-status quo. Int J Colorectal Dis 2014;29:139-145.
[PubMed]
12.
Hruban RH, Canto MI, Goggins M, et al.: Update on familial pancreatic cancer. Adv Surg 2010;44:293-311.
[PubMed]
13.
Kowalewski A, Szylberg L, Saganek M, et al.: Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol 2018;144:1503-1507.
[PubMed]
14.
Saiki Y, Horii A: Molecular pathology of pancreatic cancer. Pathol Int 2014;64:10-19.
[PubMed]
15.
Benzel J, Fendrich V: Molecular characterization and pathogenesis of intraductal papillary mucinous neoplasms of the pancreas. Eur Surg Res 2015;55:352-363.
[PubMed]
16.
Crippa S, Salvia R, Warshaw AL, et al.: Mucinous cystic neoplasm of the pancreas is not an aggressive entity: Lessons from 163 resected patients. Ann Surg 2008;247:571-579.
[PubMed]
17.
Daniell J, Plazzer JP, Perera A, Macrae F: An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: A review. Fam Cancer 2018;17:421-427.
[PubMed]
18.
Cremin C, Howard S, Le L, et al.: CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of familial atypical multiple mole melanoma (FAMMM) syndrome. Hered Cancer Clin Pract 2018;16:7.
[PubMed]
19.
Matsubayashi H, Takaori K, Morizane C, et al.: Familial pancreatic cancer: Concept, management and issues. World J Gastroenterol 2017;23:935-948.
[PubMed]
20.
Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr, et al.: Familial pancreatic cancer (Part 1): Genetic pathology review. Nebr Med J 1989;74:109-112.
[PubMed]
21.
Canto MI, Harinck F, Hruban RH, et al.: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-347.
[PubMed]
22.
Benzel J, Fendrich V: Chemoprevention and treatment of pancreatic cancer: Update and review of the literature. Digestion 2018;97:275-287.
[PubMed]
23.
Whitcomb DC, Shelton CA, Brand RE: Genetics and genetic testing in pancreatic cancer. Gastroenterology 2015;149:1252-1264.
[PubMed]
24.
Potjer TP, Schot I, Langer P, et al.: Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 2013;19:442-449.
[PubMed]
25.
Bartsch DK, Gress TM, Langer P: Familial pancreatic cancer-current knowledge. Nat Rev Gastroenterol Hepatol 2012;9:445-453.
[PubMed]
26.
Brand RE, Lerch MM, Rubinstein WS, et al.: Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56:1460-1469.
[PubMed]
27.
Schneider R, Slater EP, Sina M, et al.: German national case collection for familial pancreatic cancer (FaPaCa): Ten years experience. Fam Cancer 2011;10:323-330.
[PubMed]
28.
McFaul CD, Greenhalf W, Earl J, et al.: Anticipation in familial pancreatic cancer. Gut 2006;55:252-258.
[PubMed]
29.
Rustgi AK: Familial pancreatic cancer: Genetic advances. Genes Dev 2014;28:1-7.
[PubMed]
30.
Humphris JL, Johns AL, Simpson SH, et al.: Clinical and pathologic features of familial pancreatic cancer. Cancer 2014;120:3669-3675.
[PubMed]
31.
Connor AA, Gallinger S: Hereditary pancreatic cancer syndromes. Surg Oncol Clin N Am 2015;24:733-764.
[PubMed]
32.
Notta F, Chan-Seng-Yue M, Lemire M, et al.: Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 2017;542:124.
[PubMed]
33.
Yamaguchi J, Yokoyama Y, Kokuryo T, et al.: Cells of origin of pancreatic neoplasms. Surg Today 2018;48:9-17.
[PubMed]
34.
Collisson EA, Sadanandam A, Olson P, et al.: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-503.
[PubMed]
35.
Torres C, Grippo PJ: Pancreatic cancer subtypes: A roadmap for precision medicine. Ann Med 2018;50:277-287.
[PubMed]
36.
Janky R, Binda MM, Allemeersch J, et al.: Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer 2016;16:632.
[PubMed]
37.
Bailey P, Chang DK, Nones K, et al.: Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52.
[PubMed]
38.
Shi C, Klein AP, Goggins M, et al.: Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009;15:7737-7743.
[PubMed]
39.
Brune K, Abe T, Canto M, et al.: Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006;30:1067-1076.
[PubMed]
40.
van Lier MG, Wagner A, Mathus-Vliegen EM, et al.: High cancer risk in Peutz-Jeghers syndrome: A systematic review and surveillance recommendations. Am J Gastroenterol 2010;105:1258-1264; author reply 65.
[PubMed]
41.
Korsse SE, Harinck F, van Lier MG, et al.: Pancreatic cancer risk in Peutz-Jeghers syndrome patients: A large cohort study and implications for surveillance. J Med Genet 2013;50:59-64.
[PubMed]
42.
Pal A, Potjer TP, Thomsen SK, et al.: Loss-of-function mutations in the cell-cycle control gene CDKN2A impact on glucose homeostasis in humans. Diabetes 2016;65:527-533.
[PubMed]
43.
Nielsen FC, van Overeem Hansen T, Sorensen CS: Hereditary breast and ovarian cancer: New genes in confined pathways. Nat Rev Cancer 2016;16:599-612.
[PubMed]
44.
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al.: Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med Genet 2005;42:711-719.
[PubMed]
45.
Cavanagh H, Rogers KM: The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract 2015;13:16.
[PubMed]
46.
DaVee T, Coronel E, Papafragkakis C, et al.: Pancreatic cancer screening in high-risk individuals with germline genetic mutations. Gastrointest Endosc 2018;87:1443-1450.
[PubMed]
47.
Zhang J, Chen X: p53 tumor suppressor and iron homeostasis. FEBS J 2018 doi:10.1111/febs.14638 [Epub ahead of print] .
[PubMed]
48.
Walcott FL, Patel J, Lubet R, et al.: Hereditary cancer syndromes as model systems for chemopreventive agent development. Semin Oncol 2016;43:134-145.
[PubMed]
49.
Bujanda L, Herreros-Villanueva M: Pancreatic cancer in lynch syndrome patients. J Cancer 2017;8:3667-3674.
[PubMed]
50.
Kunkel TA, Erie DA: Eukaryotic mismatch repair in relation to DNA replication. Annu Rev Genet 2015;49:291-313.
[PubMed]
51.
Schnell U, Cirulli V, Giepmans BN: EpCAM: structure and function in health and disease. Biochim Biophys Acta 2013;1828:1989-2001.
[PubMed]
52.
Bulow S: [Familial adenomatous polyposis]. Ugeskr Laeger 2013;175:1335-1339.
[PubMed]
53.
Hankey W, Frankel WL, Groden J: Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: Implications for therapeutic targeting. Cancer Metastasis Rev 2018;37:159-172.
[PubMed]
54.
Teive HA, Moro A, Moscovich M, et al.: Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome. J Neurol Sci 2015;355:3-6.
[PubMed]
55.
Solomon S, Das S, Brand R, Whitcomb DC: Inherited pancreatic cancer syndromes. Cancer J 2012;18:485-491.
[PubMed]
56.
Carrera S, Sancho A, Azkona E, et al.: Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract 2017;15:9.
[PubMed]
57.
Berger ND, Stanley FKT, Moore S, Goodarzi AA: ATM-dependent pathways of chromatin remodelling and oxidative DNA damage responses. Philos Trans R Soc Lond B Biol Sci 2017;372:pii:20160283.
[PubMed]
58.
Mastoraki A, Tzortzopoulou A, Tsela S, et al.: Hereditary pancreatitis: Dilemmas in differential diagnosis and therapeutic approach. J Gastrointest Cancer 2014;45:22-26.
[PubMed]
59.
Singhi AD, Pai RK, Kant JA, et al.: The histopathology of PRSS1 hereditary pancreatitis. Am J Surg Pathol 2014;38:346-353.
[PubMed]
60.
Pelaez-Luna M, Robles-Diaz G, Canizales-Quinteros S, Tusie-Luna MT: PRSS1 and SPINK1 mutations in idiopathic chronic and recurrent acute pancreatitis. World J Gastroenterol 2014;20:11788-11792.
[PubMed]
61.
Jalaly NY, Moran RA, Fargahi F, et al.: An evaluation of factors associated with pathogenic PRSS1, SPINK1, CTFR, and/or CTRC genetic variants in patients with idiopathic pancreatitis. Am J Gastroenterol 2017;112:1320-1329.
[PubMed]
62.
Ooi CY, Durie PR: Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros 2012;11:355-362.
[PubMed]
63.
Yamada A, Komaki Y, Komaki F, et al.: Risk of gastrointestinal cancers in patients with cystic fibrosis: A systematic review and meta-analysis. Lancet Oncol 2018;19:758-767.
[PubMed]
64.
Maisonneuve P, Marshall BC, Lowenfels AB: Risk of pancreatic cancer in patients with cystic fibrosis. Gut 2007;56:1327-1328.
[PubMed]
65.
Jiang W, Zhuang C, Zheng L, Wang X: Role of PALB2 polymorphisms with regard to susceptibility to female breast cancer risk in the Chinese population. Genet Test Mol Biomarkers 2016;20:229-234.
[PubMed]
66.
Camara SN, Yin T, Yang M, et al.: High risk factors of pancreatic carcinoma. J Huazhong Univ Sci Technolog Med Sci 2016;36:295-304.
[PubMed]
67.
Becker AE, Hernandez YG, Frucht H, Lucas AL: Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. World J Gastroenterol 2014;20:11182-11198.
[PubMed]
68.
Luo AJ, Feng RH, Wang XW, Wang FZ: Older age at first birth is a risk factor for pancreatic cancer: A meta-analysis. Hepatobiliary Pancreat Dis Int 2016;15:125-130.
[PubMed]
69.
Grigor'eva IN, Efimova OV, Suvorova TS, Tov NL: [Pancreatitis, pancreatic cancer and obesity: hypothesis and facts]. Eksp Klin Gastroenterol 2014:4-10.
[PubMed]
70.
Beg MS, Dwivedi AK, Ahmad SA, et al.: Impact of diabetes mellitus on the outcome of pancreatic cancer. PLoS One 2014;9:e98511.
[PubMed]
71.
Pinho AV, Chantrill L, Rooman I: Chronic pancreatitis: A path to pancreatic cancer. Cancer Lett 2014;345:203-209.
[PubMed]
72.
Risch HA, Yu H, Lu L, Kidd MS: ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: A case-control study. J Natl Cancer Inst 2010;102:502-505.
[PubMed]
73.
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al.: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009;41:986-990.
[PubMed]
74.
Tersmette AC, Petersen GM, Offerhaus GJ, et al.: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-744.
[PubMed]
75.
Finch MD, Howes N, Ellis I, et al.: Hereditary pancreatitis and familial pancreatic cancer. Digestion 1997;58:564-569.
[PubMed]
76.
Hruban RH, Petersen GM, Goggins M, et al.: Familial pancreatic cancer. Ann Oncol 1999;10(Suppl 4):69-73.
[PubMed]
77.
Bertens KA, Massman JD 3rd, Helton S, et al.: Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged? J Surg Oncol 2018 doi: 10.1002/jso.25060 [Epub ahead of print].
[PubMed]
78.
Tang CC, Draucker C, Tejani M, Von Ah D: Symptom experiences in patients with advanced pancreatic cancer as reported during healthcare encounters. Eur J Cancer Care (Engl) 2018;27:e12838.
[PubMed]
79.
Tang CC, Von Ah D, Fulton JS: The symptom experience of patients with advanced pancreatic cancer: An integrative review. Cancer Nurs 2018;41:33-44.
[PubMed]
80.
Del Chiaro M, Segersvard R, Lohr M, Verbeke C: Early detection and prevention of pancreatic cancer: Is it really possible today? World J Gastroenterol 2014;20:12118-12131.
[PubMed]
81.
Goral V: Pancreatic cancer: Pathogenesis and diagnosis. Asian Pac J Cancer Prev 2015;16:5619-5624.
[PubMed]
82.
Zhou B, Xu JW, Cheng YG, et al.: Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer 2017;141:231-241.
[PubMed]
83.
Chan A, Prassas I, Dimitromanolakis A, et al.: Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 2014;20:5787-5795.
[PubMed]
84.
Lu D, Wang J, Shi X, et al.: AHNAK2 is a potential prognostic biomarker in patients with PDAC. Oncotarget 2017;8:31775-1784.
[PubMed]
85.
New Biomarker Identified for PDAC. Cancer Discov 2017;7:Of3.
86.
Ray K: Pancreatic cancer: Biomarkers for the early detection of PDAC. Nat Rev Gastroenterol Hepatol 2017;14:504-505.
[PubMed]
87.
Frampton AE, Prado MM, Lopez-Jimenez E, et al.: Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget 2018;9:19006-19013.
[PubMed]
88.
Lewis JM, Vyas AD, Qiu Y, et al.: Integrated analysis of exosomal protein biomarkers on alternating current electrokinetic chips enables rapid detection of pancreatic cancer in patient blood. ACS Nano 2018;12:3311-3320.
[PubMed]
89.
Takahasi K, Iinuma H, Wada K, et al.: Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2018;25:155-161.
[PubMed]
90.
Campa D, Pastore M, Capurso G, et al.: Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Int J Cancer 2018;142:290-296.
[PubMed]
91.
Canto MI, Hruban RH, Fishman EK, et al.: Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804; quiz e14-15.
[PubMed]
92.
Kikuyama M, Kamisawa T, Kuruma S, et al.: Early diagnosis to improve the poor prognosis of pancreatic cancer. Cancers (Basel) 2018;10:pii:E48.
[PubMed]
93.
Poruk KE, Firpo MA, Mulvihill SJ: Screening for pancreatic cancer. Adv Surg 2014;48:115-136.
[PubMed]
94.
Hanada K, Amano H, Abe T: Early diagnosis of pancreatic cancer: Current trends and concerns. Ann Gastroenterol Surg 2017;1:44-51.
[PubMed]
95.
Mastoraki A, Chatzimavridou-Grigoriadou V, Chatzipetrou V, et al.: Familial pancreatic cancer: Challenging diagnostic approach and therapeutic management. J Gastrointest Cancer 2014;45:256-261.
[PubMed]
96.
Bartsch DK, Slater EP, Carrato A, et al.: Refinement of screening for familial pancreatic cancer. Gut 2016;65:1314-1321.
[PubMed]
97.
Walsh RM, Saavedra JR, Lentz G, et al.: Improved quality of life following total pancreatectomy and auto-islet transplantation for chronic pancreatitis. J Gastrointest Surg 2012;16:1469-1477.
[PubMed]
98.
Chang MC, Wu CH, Yang SH, et al.: Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan. Am J Cancer Res 2017;7:357-369.
[PubMed]
99.
Capurso G, Signoretti M, Valente R, et al.: Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc 2015;7:833-842.
[PubMed]
100.
Bruenderman E, Martin RC 2nd: A cost analysis of a pancreatic cancer screening protocol in high-risk populations. Am J Surg 2015;210:409-416.
[PubMed]
101.
Harinck F, Nagtegaal T, Kluijt I, et al.: Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 2011;13:1015-1024.
[PubMed]
102.
Hart SL, Torbit LA, Crangle CJ, et al.: Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Psychooncology 2012;21:1324-1330.
[PubMed]
103.
Maheu C, Vodermaier A, Rothenmund H, et al.: Pancreatic cancer risk counselling and screening: Impact on perceived risk and psychological functioning. Fam Cancer 2010;9:617-624.
[PubMed]
104.
Carrato A, Falcone A, Ducreux M, et al.: A systematic review of the burden of pancreatic cancer in Europe: Real-world impact on survival, quality of life and costs. J Gastrointest Cancer 2015;46:201-211.
[PubMed]
105.
Hjelmgren J, Ceberg J, Persson U, Alvegard TA: The cost of treating pancreatic cancer-a cohort study based on patients' records from four hospitals in Sweden. Acta Oncol 2003;42:218-226.
[PubMed]
106.
Tingstedt B, Andersson E, Flink A, et al.: Pancreatic cancer, healthcare cost, and loss of productivity: A register-based approach. World J Surg 2011;35:2298-2305.
[PubMed]
107.
Pasquali C, Sperti C, Filipponi C, Pedrazzoli S: Epidemiology of pancreatic cancer in Northeastern Italy: Incidence, resectability rate, hospital stay, costs and survival (1990-1992). Dig Liver Dis 2002;34:723-731.
[PubMed]
108.
Muller-Nordhorn J, Bruggenjurgen B, Bohmig M, et al.: Direct and indirect costs in a prospective cohort of patients with pancreatic cancer. Aliment Pharmacol Ther 2005;22:405-415.
[PubMed]
109.
Bachmann M, Peters T, Harvey I: Costs and concentration of cancer care: Evidence for pancreatic, oesophageal and gastric cancers in National Health Service hospitals. J Health Serv Res Policy 2003;8:75-82.
[PubMed]
110.
Lu C, Xu CF, Wan XY, et al.: Screening for pancreatic cancer in familial high-risk individuals: A systematic review. World J Gastroenterol 2015;21:8678-8686.
[PubMed]
111.
Signoretti M, Bruno MJ, Zerboni G, et al.: Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. United European Gastroenterol J 2018;6:489-499.
[PubMed]
112.
Corral JE, Mareth KF, Riegert-Johnson DL, et al.: Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: A meta-analysis of cohort studies. Clin Gastroenterol Hepatol 2018;pii: S1542-3565(18)30498-1.
[PubMed]
113.
Brentnall TA, Bronner MP, Byrd DR, et al.: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-255.
[PubMed]
114.
Al-Sukhni W, Borgida A, Rothenmund H, et al.: Screening for pancreatic cancer in a high-risk cohort: An eight-year experience. J Gastrointest Surg 2012;16:771-783.
[PubMed]
115.
Langer P, Kann PH, Fendrich V, et al.: Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58:1410-1418.
[PubMed]
116.
Barone E, Corrado A, Gemignani F, Landi S: Environmental risk factors for pancreatic cancer: An update. Arch Toxicol 2016;90:2617-2642.
[PubMed]
117.
Slater EP, Langer P, Niemczyk E, et al.: PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010;78:490-494.
[PubMed]
118.
Slater EP, Langer P, Fendrich V, et al.: Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 2010;9:335-343.
[PubMed]
119.
Rieder H, Sina-Frey M, Ziegler A, et al.: German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families. Onkologie 2002;25:262-266.
[PubMed]
120.
Rossi ML, Rehman AA, Gondi CS: Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014;20:11142-11159.
[PubMed]
You do not currently have access to this content.